Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
71.4M
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
54.7M
-
Shares change
-
-9.58M
-
Total reported value, excl. options
-
$78.2M
-
Value change
-
-$14.7M
-
Number of buys
-
57
-
Number of sells
-
-70
-
Price
-
$1.43
Significant Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) as of Q2 2025
141 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.7M shares
of 71.4M outstanding shares and own 76.67% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS LP (7.42M shares), Lynx1 Capital Management LP (7.1M shares), Soleus Capital Management, L.P. (6.98M shares), ORBIMED ADVISORS LLC (6.83M shares), MORGAN STANLEY (4.75M shares), VANGUARD GROUP INC (3.02M shares), BANK OF AMERICA CORP /DE/ (2.01M shares), BlackRock, Inc. (1.83M shares), Bain Capital Life Sciences Investors, LLC (1.11M shares), and MILLENNIUM MANAGEMENT LLC (1.1M shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.